Mikuriya TH (1969) Marijuana in medicine: past, present and future. Calif Med 110(1):34–40

Moreno-Navarrete JM, Catalan V, Whyte L, Diaz-Arteaga A, Vazquez-Martinez R, Rotellar F

(2012) The L-α-lysophosphatidylinositol/GPR55 system and its potential role in human obesity.

Diabetes 61:281–291

Müller-Vahl KR, Schneider U, Emrich HM (1999) Nabilone increases choreatic movements in

Huntington’s disease. Mov Disord 14:1038–1040

Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for

cannabinoids. Nature 365:61–65

Myers RH (2004) Huntington's disease genetics. NeuroRx 1:255–262

Novota A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O et al (2011) A randomized,

double-blind, placebo controlled, parallel-group, enriched-design study of nabiximols (Sativex),

as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J

Neurol 18(9):1122–1131

Oh JH, Lee JY, Baeg MK, Han KH, Choi MG, Park JM (2013) Antineoplastic effect of WIN

55,212-2, a cannabinoid agonist, in a murine xenograft model of gastric cancer. Chemotherapy

59(3):200–206

Pacula RL, Smart R (2017) Medical marijuana and marijuana legalization. Annu Rev Clin Psychol

13:397–419

Palazuelos J, Aguado T, Pazos MR, Julien B, Carrasco C, Resel E (2009) Microglial CB2

cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 132:

3152–3164

Pan ST, Li ZL, He ZX, Qiu JX, Zhou SF (2016) Molecular mechanisms for tumour resistance to

chemotherapy. Clin Exp Pharmacol Physiol 43(8):723–737

Patsos HA, Greenhough A, Hicks DJ, Al Kharusi M, Collard TJ, Lane JD et al (2010) The

endogenous cannabinoid, anandamide, induces COX-2-dependent cell death in apoptosis-

resistant colon cancer cells. Int J Oncol 37:187–193

Petro DJ, Ellenberger C Jr (1981) Treatment of human spasticity with delta 9-tetrahydrocannabinol.

J Clin Pharmacol 21(8–9 Suppl):413S–416S

Pineiro R, Maffucci T, Falasca M (2011) The putative cannabinoid receptor GPR55 defines a novel

autocrine loop in cancer cell proliferation. Oncogene 30:142–152

Preet A, Ganju RK, Groopman JE (2008) Delta9-tetrahydrocannabinol inhibits epithelial growth

factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo.

Oncogene 27:339–346

Ramer R, Bublitz K, Freimuth N, Merkord J, Rohde H, Haustein M et al (2012) Cannabidiol

inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. FASEB J

26:1535–1548

Ramírez BG, Blázquez C, Gómez del Pulgar T, Guzmán M, de Ceballos ML (2005) Prevention of

Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of

microglial activation. J Neurosci 25:1904–1913

Read BE (1936) Chinese medicinal plants. In: Peking natural history bulletin. MIT Press, Beijing,

p 152

Roberto D, Klotz LH, Venkateswaran V (2019) Cannabinoid WIN 55,212-2 induces cell cycle

arrest and apoptosis, and inhibits proliferation, migration, invasion, and tumor growth in

prostate cancer in a cannabinoid receptor 2 dependent manner. Prostate 79(2):151–159

Robson P (2001) Therapeutic aspects of cannabis and cannabinoids. Br J Psychiatry 178:107–115

Roos RA (2010) Huntington's disease: a clinical review. Orphanet J Rare Dis 5:40

Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J (2007) The orphan receptor

GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152:1092–1101

Sánchez C, de Ceballos ML, Gomez del Pulgar T, Rueda D, Corbacho C, Velasco G et al (2001)

Inhibition of glioma growth in vivo by selective activation of the CB2 cannabinoid receptor.

Cancer Res 61:5784–5789

Sarfaraz S, Afaq F, Adhami VM, Malik A, Mukhtar H (2006) Cannabinoid receptor agonist-

induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation

of ERK1/2 leading to G1 cell cycle arrest. J Biol Chem 281:39480–39491

200

S. Singh et al.